<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112643</url>
  </required_header>
  <id_info>
    <org_study_id>AAAL9502</org_study_id>
    <nct_id>NCT02112643</nct_id>
  </id_info>
  <brief_title>Selenium in Mild Thyroid Eye Disease in North America</brief_title>
  <acronym>S-ITEDS</acronym>
  <official_title>Selenium - ITEDS: A North American Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Thyroid Eye Disease Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sodium selenite is helpful in the treatment&#xD;
      of mild thyroid eye disease in North America.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid eye disease (TED) is a disease in which the soft tissues surrounding the eye can&#xD;
      become inflamed, scarred, and at times permanently damaged in an autoimmune reaction highly&#xD;
      associated with abnormal thyroid hormone levels. Some patients have much more severe TED than&#xD;
      others, but overall, most patients reach a point with relatively stable TED after 1 to 2&#xD;
      years. A recent European study showed that oral selenium, a trace mineral involved in&#xD;
      anti-oxidation and immune regulation, could actually alter the course of mild TED, lessening&#xD;
      its signs and symptoms and even improving the quality of life of those who took it. The&#xD;
      investigators would like to perform a sister study throughout North America. In this&#xD;
      randomized, double-blinded, multi-center trial, some subjects with mild TED would be given&#xD;
      100 micrograms of sodium selenite twice a day; others would receive a placebo. Signs,&#xD;
      symptoms, and quality of life would be measured at regular intervals throughout the 6 month&#xD;
      period of drug administration, and for 6 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 2015</start_date>
  <completion_date type="Actual">November 16, 2016</completion_date>
  <primary_completion_date type="Actual">November 16, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Six months</time_frame>
    <description>Using GO-QOL score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Twelve months</time_frame>
    <description>GO-QOL score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Thyroid Eye Disease</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Thyroid Eye Disease</measure>
    <time_frame>Twelve months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Clinical Activity Score</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Clinical Activity Score</measure>
    <time_frame>Twelve months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Six months</time_frame>
    <description>TED-PRO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Twelve months</time_frame>
    <description>TED-PRO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Six months</time_frame>
    <description>TED-QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Twelve months</time_frame>
    <description>TED-QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in development of optic neuropathy</measure>
    <time_frame>Twelve months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Inflammatory Index</measure>
    <time_frame>Six months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Inflammatory Index</measure>
    <time_frame>Twelve months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Inflammatory Index</measure>
    <time_frame>Six months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Inflammatory Index</measure>
    <time_frame>Twelve months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diplopia score</measure>
    <time_frame>Six months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diplopia score</measure>
    <time_frame>Twelve months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diplopia score</measure>
    <time_frame>Six months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diplopia score</measure>
    <time_frame>Twelve months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in degrees of restriction</measure>
    <time_frame>Six months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in degrees of restriction</measure>
    <time_frame>Twelve months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in degrees of restriction</measure>
    <time_frame>Six months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in degrees of restriction</measure>
    <time_frame>Twelve months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in exophthalmos scores</measure>
    <time_frame>Six months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in exophthalmos scores</measure>
    <time_frame>Twelve months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in exophthalmos scores</measure>
    <time_frame>Six months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in exophthalmos scores</measure>
    <time_frame>Twelve months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in eyelid aperture</measure>
    <time_frame>Six months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in eyelid aperture</measure>
    <time_frame>Twelve months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in eyelid aperture</measure>
    <time_frame>Six months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in eyelid aperture</measure>
    <time_frame>Twelve months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fasting glucose level</measure>
    <time_frame>Six months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Thyroid Associated Ophthalmopathies</condition>
  <arm_group>
    <arm_group_label>Selenium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 micrograms of sodium selenate will be taken orally twice daily (total 200 micrograms daily) for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo pill will be taken orally twice daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium selenate</intervention_name>
    <description>A 100 microgram pill will be orally administered twice a day for 6 months.</description>
    <arm_group_label>Selenium</arm_group_label>
    <other_name>Selenium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Able to swallow pills&#xD;
&#xD;
          -  Mild thyroid eye disease requiring no past treatment other than ophthalmic drops or&#xD;
             ointment&#xD;
&#xD;
          -  Euthyroid: at least 2 months if on medication irregardless of thyroidectomy status; at&#xD;
             least 6 months after radioiodine therapy; if euthyroid for the year prior to&#xD;
             enrollment, needs normal thyroid-stimulating hormone (TSH) within last 3 months; if&#xD;
             uncontrolled for the year prior to enrollment, needs normal TSH and free T4 within&#xD;
             last 3 months; if TSH low, needs normal T3 and free T4&#xD;
&#xD;
          -  If you are currently taking any selenium supplementation, you will be asked to&#xD;
             discontinue its usage, &quot;wash out&quot;, for 1 month before you are enrolled.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Moderate or severe thyroid eye disease (based upon International Thyroid Eye Disease&#xD;
             Society VISA form), including: grade 2 chemosis or lid edema; corneal exposure with&#xD;
             threat of or resulting in perforation; optic neuropathy; grade 3 restriction of any&#xD;
             extraocular muscle&#xD;
&#xD;
          -  Double vision (diplopia) in primary or reading positions&#xD;
&#xD;
          -  Duration of thyroid eye disease greater than 12 months (as per patient history)&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Severe systemic illness (defined by treating physician)&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Micahel Kazim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Thyroid Eye Disease Society</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://thyroideyedisease.org/</url>
    <description>This is the International Thyroid Eye Disease Society (ITEDS) website.</description>
  </link>
  <reference>
    <citation>Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W; European Group on Graves' Orbitopathy. Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011 May 19;364(20):1920-31. doi: 10.1056/NEJMoa1012985.</citation>
    <PMID>21591944</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroid eye disease</keyword>
  <keyword>Thyroid orbitopathy</keyword>
  <keyword>Graves' orbitopathy</keyword>
  <keyword>Graves' ophthalmopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
    <mesh_term>Selenic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

